U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07142954) titled 'Epidemiology and Biomarker Study in Alzheimer's Disease' on Aug. 20.
Brief Summary: Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts.
Participation in AACU will last approximately 7 years.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Intervention:
OTHER: P-tau217 Test
A plasma test measuring phosphorylated tau at Position 217 (P-tau217).
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by HT Syndication....